文献速递哮喘

补体C3与过敏性哮喘:一项普通人群队列研究

Complement C3 and allergic asthma: a cohort study of the general population.
PubMed 文献 · Eur Respir J · 2021-02-04

在101 029名普通人群中,基线血浆补体C3最高三分位(>1.19 g·L-1)者哮喘住院风险较最低三分位(<1.03 g·L-1)升高,校正后HR为1.23(95%CI 1.04-1.45);在2248名过敏性哮喘患者中,最高三分位(>1.24 g·L-1)者急性加重风险亦升高,校正后IRR为1.69(95%CI 1.06-2.72)。

要点

  • 高血浆补体C3与普通人群哮喘住院风险升高相关(HR 1.23)。
  • 过敏性哮喘患者中高补体C3与急性加重风险升高相关(IRR 1.69)。
  • C3 rs448260 CC基因型与哮喘住院风险升高相关(HR 1.17)。

核心结论

  • 高血浆补体C3浓度与普通人群哮喘住院风险升高相关,并与过敏性哮喘患者急性加重风险升高相关。

研究设计与样本

  • 前瞻性队列研究,纳入101 029名哥本哈根普通人群研究对象,基线测量血浆补体C3并检测rs1065489、rs429608、rs448260基因型。
  • 在2248名过敏性哮喘患者中进一步评估哮喘急性加重风险。

主要发现

  • 血浆补体C3最高三分位(>1.19 g·L-1)者哮喘住院风险较最低三分位(<1.03 g·L-1)升高,校正后HR为1.23(95%CI 1.04-1.45)。
  • C3 rs448260 CC基因型较AA基因型哮喘住院风险升高,观察HR为1.17(95%CI 1.06-1.28)。
  • 高血浆补体C3与血嗜酸性粒细胞和IgE水平升高相关(趋势P≤6×10-9);仅SKIV2L rs429608基因型与血嗜酸性粒细胞计数(P=3×10-4)和IgE水平(P=3×10-4)正相关。
  • 过敏性哮喘中,血浆补体C3最高三分位(>1.24 g·L-1)者急性加重风险较最低三分位(<1.06 g·L-1)升高,校正后IRR为1.69(95%CI 1.06-2.72)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Complement C3 plays a role in asthma development and severity. We tested the hypothesis that high plasma complement C3 concentration is associated with high risks of asthma hospitalisation and exacerbation.We prospectively assessed the risk of asthma hospitalisation in 101 029 individuals from the Copenhagen General Population Study with baseline measurements of plasma complement C3, and genotyped for rs1065489, rs429608 and rs448260 determining levels of complement C3. Risk of asthma exacerbation was further assessed in 2248 individuals with allergic asthma.The multivariable adjusted hazard ratio of asthma hospitalisation was 1.23 (95% CI 1.04-1.45) for individuals in the highest tertile (>1.19 g·L-1) of plasma complement C3 compared with those in the lowest tertile (<1.03 g·L-1). The C3 rs448260 genotype was associated with risk of asthma hospitalisation with an observed hazard ratio of 1.17 (95% CI 1.06-1.28) for the CC genotype compared with the AA genotype. High plasma complement C3 was associated with high levels of blood eosinophils and IgE (p for trends ≤6×10-9), but only the SKIV2L rs429608 genotype was positively associated with blood eosinophil count (p=3×10-4) and IgE level (p=3×10-4). In allergic asthma, the multivariable adjusted incidence rate ratio for risk of exacerbation was 1.69 (95% CI 1.06-2.72) for individuals in the highest plasma complement C3 tertile (>1.24 g·L-1) versus the lowest (<1.06 g·L-1).In conclusion, a high concentration of plasma complement C3 was associated with a high risk of asthma hospitalisation in the general population and with a high risk of asthma exacerbation in individuals with allergic asthma. Our findings support a causal role of the complement system in asthma severity.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Vedel-Krogh S, Rasmussen KL, Nordestgaard BG, et al. Complement C3 and allergic asthma: a cohort study of the general population. Eur Respir J. 2021. PMID: 32817007. doi:10.1183/13993003.00645-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。